Rosuvastatin IR Pellets Manufacturer in India
Rosuvastatin IR Pellets are pharmaceutical-grade immediate-release multiparticulate pellets developed for incorporation into oral dosage forms where rapid release of the active ingredient is required. The pellet system provides a flexible platform for active loading, pellet-size control, content uniformity and capsule-filling applications.
For pharmaceutical formulations, the active ingredient is generally Rosuvastatin Calcium. Rosuvastatin Calcium has CAS Number 147098-20-2, molecular formula C₄₄H₅₄CaF₂N₆O₁₂S₂, and molecular weight 1001.1 g/mol. These values describe the active ingredient and should not be interpreted as the assay or loading of the finished pellets.
Commercial pellet portfolios document 10% and 20% Rosuvastatin IR Pellets. These same strengths are also listed in the researched commercial product portfolio, but the final available strength for SDP should be aligned with the current approved SDP specification.
Rosuvastatin IR Pellets use multiparticulate technology in which the active ingredient is distributed throughout individual pharmaceutical pellets. The formulation can be designed to provide rapid release while maintaining suitable physical characteristics for downstream oral dosage-form manufacturing.
Important formulation characteristics include:
Immediate-release pellet systems can provide formulation flexibility because the total dose is distributed across numerous individual pellets rather than being concentrated in a single unit.
Commercial product portfolios list 10% and 20% Rosuvastatin IR Pellets. These represent finished-pellet active loading and should not be confused with the assay specification of Rosuvastatin Calcium API.
For the SDP product page, the strength should be displayed as:
provided these strengths correspond to the currently approved SDP product specification.
Rosuvastatin IR Pellets are intended for immediate-release multiparticulate oral formulation development. The formulation can be optimized for rapid and reproducible release of the active ingredient.
Potential applications include:
The final dissolution requirement should be established according to the validated finished-product specification.
Pellet-based formulations can provide useful flexibility for capsule manufacturing. Consistent pellet size, density and flow properties can support reproducible filling and distribution of the active ingredient.
Important capsule-filling characteristics include:
The exact pellet size and physical specifications should be controlled according to the individual product specification.
The immediate-release performance of Rosuvastatin IR Pellets depends on the formulation composition and manufacturing process.
Important factors include:
For an immediate-release formulation, the finished pellet system should be developed to achieve the required release profile within the validated dissolution method.
Finished-product dissolution limits should be taken from the approved SDP specification rather than using generic commercial values.
Accurate active loading is an important quality attribute for Rosuvastatin IR Pellets. Uniform distribution of Rosuvastatin Calcium throughout the pellet population helps support consistent assay and dosage-unit performance.
The specification should distinguish between:
API specification:
The applicable quality requirements for Rosuvastatin Calcium as the pharmaceutical ingredient.
Finished pellet specification:
The actual Rosuvastatin loading, assay, content uniformity, moisture, physical characteristics and dissolution requirements of the finished pellets.
Therefore, the API assay should not be copied directly into the finished-pellet assay specification.
Rosuvastatin IR Pellets can be developed for pharmaceutical formulations requiring immediate release and multiparticulate technology.
Formulation development may evaluate:
Process optimization helps establish suitable physical properties while maintaining the intended immediate-release performance.
Swapnroop provides Rosuvastatin IR Pellets for pharmaceutical formulation applications, focusing on immediate-release multiparticulate technology, controlled active loading, pellet uniformity and downstream capsule-filling requirements.
As a Rosuvastatin IR Pellets Manufacturer in India, the product can be positioned for pharmaceutical formulation companies and bulk procurement requirements. Relevant SEO terms include Rosuvastatin Calcium IR Pellets, Rosuvastatin Immediate Release Pellets, Rosuvastatin Pharmaceutical Pellets, Rosuvastatin IR Pellets Manufacturer India, Rosuvastatin Pellets Supplier India, Rosuvastatin Calcium Pellets Manufacturer India, Rosuvastatin Multiparticulate Pellets, Rosuvastatin Capsule Filling Pellets and Rosuvastatin Bulk Pellets.
Rosuvastatin IR Pellets can be supplied according to approved product and customer requirements, including:
The final available strength and packaging configuration should be confirmed against the current SDP product specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 0.5% |